Depemokimab Trial for COPD
Phase 3
981
about 4.2 years
40–80
4 sites in FL, SC, TX
About this study
Researchers are testing depemokimab, a new medication, as an add-on treatment for adults with moderate to severe COPD and type 2 inflammation. The trial will last for 1522 days (approximately 3 years) and involve about 981 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Depemokimab
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
monoclonal antibody
Secondary: Annualized Rate of Exacerbations Requiring Emergency Department (ED) Visit or Hospitalization, Change From Baseline in Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease (E-RS:COPD) Total Score at Week 52, Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score at Week 52
Respiratory